Seattle drug firm ZymoGenetics has taken Bristol-Myers Squibb (BMS)
to court for infringement of its fusion protein technology patents
by several products, including arthritis medication Orencia
Germany's Merck has announced its biggest investment in
pharmaceuticals in its 338-year-old history, as its top-selling
oncology drug Erbitux (cetuximab) has driven the company to
allocate €190m for the construction of its first...
US generic drugmaker Mylan has agreed to spend around $736m
(€573.4m) to acquire a controlling stake in Matrix, an Indian
manufacturer of active pharmaceutical ingredients (APIs) and solid
oral dosage forms, as relentless competition...
Scientists believe they have discovered a novel way in treating
people suffering from anthrax poisoning, which could overcome the
problem of antibiotic resistance that is becoming increasingly
common in southern and Eastern Europe...
In the first drug master file (DMF) approval of its kind, the US
Food and Drug Administration (FDA) has approved the sale of
metformin hydrochloride tablets which are produced by an Indian
company using a pharmaceutical formulation...
Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
Industrial enzyme maker Novozymes is seeking to strengthen its
presence in the biopharmaceutical market by offering to acquire
Australian biotechnology firm Gropep for AUD83.6m (€49.6m), eager
to become a supplier of recombinant ingredients...
Biopharmaceutical firm Altus has asked contract manufacturer Althea
to produce Phase III quantities of a crystallised formulation of
human growth hormone (hGH) which can be administered subcutaneously
weekly instead of daily.
Researchers have identified a protein that is thought to defend the
intestinal against microbial invaders offering new insights into
how the intestine fends off pathogens and potentially leading to
new inflammatory bowel disease medications.
Difficulties in identifying tablets have emerged as a major issue
in a recent US survey of 150 pharmacists who are warning drugmakers
that the lack of distinct appearance in pills leads in dispensing
errors that cost more than 7,000...